65.86
Ionis Pharmaceuticals Inc stock is traded at $65.86, with a volume of 681.83K.
It is up +0.47% in the last 24 hours and up +54.17% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$65.42
Open:
$65.35
24h Volume:
681.83K
Relative Volume:
0.29
Market Cap:
$10.49B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-21.66
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+2.80%
1M Performance:
+54.17%
6M Performance:
+141.12%
1Y Performance:
+68.24%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IONS
Ionis Pharmaceuticals Inc
|
65.83 | 10.43B | 705.14M | -453.90M | -551.29M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
405.63 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.91 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.96 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
774.75 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
345.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
Apr-07-25 | Initiated | H.C. Wainwright | Buy |
Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jul-16-24 | Resumed | Jefferies | Buy |
Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
Sep-29-23 | Initiated | Raymond James | Strong Buy |
Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
Jun-07-23 | Resumed | Piper Sandler | Overweight |
May-04-23 | Upgrade | Citigroup | Sell → Neutral |
Mar-21-23 | Initiated | Bernstein | Underperform |
Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-09-22 | Resumed | Morgan Stanley | Overweight |
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mar-31-22 | Resumed | Piper Sandler | Overweight |
Mar-01-22 | Initiated | Citigroup | Sell |
Mar-01-22 | Initiated | Guggenheim | Buy |
Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
May-07-21 | Upgrade | UBS | Sell → Neutral |
Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
Dec-16-20 | Initiated | UBS | Sell |
Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
Sep-14-20 | Resumed | JP Morgan | Neutral |
Sep-02-20 | Initiated | The Benchmark Company | Hold |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Dec-13-19 | Initiated | Oppenheimer | Outperform |
Nov-13-19 | Initiated | BofA/Merrill | Buy |
Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
Aug-08-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Reiterated | Stifel | Hold |
May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-06-17 | Resumed | Goldman | Sell |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Aug-09-17 | Reiterated | Stifel | Hold |
Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals stock hits 52-week high at 64.89 USD By Investing.com - Investing.com Nigeria
What analysts say about Ionis Pharmaceuticals Inc ISI stockDividend Stock Watch & High Return Wealth Plans - earlytimes.in
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Applying big data sentiment scoring on Ionis Pharmaceuticals Inc.2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock in buy zone after pullbackWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Investor Ratings Indicate Promising Upside Potential - DirectorsTalk Interviews
Published on: 2025-09-29 03:15:49 - newser.com
What drives Ionis Pharmaceuticals Inc stock priceVolume Weighted Average Price & Minimal Investment Profits - earlytimes.in
Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Should you hold or exit Ionis Pharmaceuticals Inc. nowQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Using fundamentals and technicals on Ionis Pharmaceuticals Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Ionis Pharmaceuticals (IONS) Is Up 5.0% After Positive Phase III Results for Alexander Disease Therapy - Yahoo Finance
IONS Upgraded by Goldman Sachs with a Significant Price Target I - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Neutral at The Goldman Sachs Group - MarketBeat
Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings - MarketBeat
Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45 - MarketScreener
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
Is Ionis Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals stock price target raised to $68 by Leerink Partners - Investing.com UK
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal - sharewise.com
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology - Nasdaq
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Biogen
A Look at Ionis Pharmaceuticals’s Valuation as Zilganersen Delivers Breakthrough Results in Alexander Disease - Sahm
Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's
Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News
Barclays Maintains Overweight Rating on IONS, Raises Price Targe - GuruFocus
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits
Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target P - GuruFocus
Guggenheim Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $83.00 at Bank of America - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease - BioSpace
IONS: HC Wainwright Reiterates Buy Rating with $95 Target | IONS Stock News - GuruFocus
Ionis reports positive results for Alexander disease drug zilganersen By Investing.com - Investing.com Nigeria
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease - BioSpace
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sovran Advisors LLC - MarketBeat
Ionis Targets Ultra-Rare Disease Market With Zilganersen - insights.citeline.com
Ionis reports positive results for Alexander disease drug zilganersen - Investing.com India
Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval - Endpoints News
Ionis stock surges after positive results from Alexander disease drug By Investing.com - Investing.com Canada
Ionis reports promising data from study of Alexander disease therapy - Seeking Alpha
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial - Benzinga
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga - GuruFocus
Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease - Nasdaq
Ionis' brain disorder drug shows promise in clinical trial - TradingView
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):